A Phase II, Open-label Study to Evaluate the Efficacy and Safety of HMPL-504 in Locally Advanced/Metastatic MET-Mutation-Positive Pulmonary Sarcomatoid Carcinomas
Phase of Trial: Phase II
Latest Information Update: 20 Jul 2017
At a glance
- Drugs Savolitinib (Primary)
- Indications Lung cancer
- Focus Therapeutic Use
- Sponsors Hutchison MediPharma
- 14 Jul 2017 Planned End Date changed from 1 Jun 2018 to 1 Jun 2019.
- 14 Jul 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 10 Feb 2017 According to a Chi-Med media release, the first drug dose was administered in this trial.